DESITIN PHARMA A/S: Financial statements 2017
CVR: 19389006
Source: annual report 2017, Danish Business Authority
01/10/2016 – 30/09/2017
DESITIN PHARMA A/S (CVR 19389006) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 4,596,401 and a net result of DKK 629,530 compared with DKK 1,189,111 the year before. That is a decrease of 18% compared with the year before. Equity in the 2017 report amounted to DKK 3,602,509. The solvency ratio was 79.9%.
- Gross Profit
- DKK 4,596,401
- Profit/Loss
- DKK 629,530
- Equity
- DKK 3,602,509
- Total Assets
- DKK 4,510,679
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 4.6 mio. | 630 t. | 3.6 mio. | - |
| 2016 | - | 5.6 mio. | 1.2 mio. | 3.7 mio. | - |
| 2015 | - | 7.4 mio. | 2.4 mio. | 3.7 mio. | - |
| 2014 | - | 958 t. EUR | 287 t. EUR | 379 t. EUR | - |
| 2013 | - | 881 t. EUR | 209 t. EUR | 342 t. EUR | - |
Official annual report
Keep an eye on DESITIN PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
As of October 1, 2017, Tina Nørgaard has joined the board of directors of DESITIN PHARMA A/S.
As of October 1, 2017, Martin Schütt has joined the board of directors of DESITIN PHARMA A/S.
As of October 1, 2017, Dieter Heinrich Peitz has left the board of directors of DESITIN PHARMA A/S.
As of October 1, 2017, Michael Hanke has left the board of directors of DESITIN PHARMA A/S.
About DESITIN PHARMA A/S
DESITIN PHARMA A/S is a Danish company of the type Aktieselskab based in København V, founded in 1996. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Eli Lønne. The board consists of Philipp Andreas Bloching (chair), Eli Lønne and Oliver Christoph. The company is owned by Desitin Arzneimittel GmbH. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 2,151,761 and a net result of DKK 288,733 compared with DKK 285,567 the year before. Equity in the 2025 report amounted to DKK 7,044,140.